Skip to main content
Premium Trial:

Request an Annual Quote

CeGaT New Diagnostic Panels

CeGaT has launched a diagnostic panel for blood and immune disorders, an update and expansion of its diagnostic panel for kidney diseases, and BRCA1/2 testing for ovarian cancer. The new panel for blood and immune disorders contains 14 subpanels that include 297 genes associated with anemia, coagulation disorders, thrombocytopenia, bone marrow failure syndromes, antibody deficiencies, complement deficiencies, autoinflammatory disease, and immune dysregulation. The diagnostic panel for kidney diseases has been updated and expanded to include 182 analyzed genes. In particular, the subpanels for nephronophthisis, renal dysplasia, renal agenesia, CAKUT, nephrotic syndrome, and focal segmental glomerulosclerosis have been expanded to include various differential diagnoses. The new BRCA1/2 diagnostic test determines whether a patient is a good candidate for olaparib therapy, which requires the presence of a mutation in the BRCA1 or BRCA2 genes.